Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
Crossref DOI link: https://doi.org/10.1186/s13075-015-0825-9
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Strand, Vibeke
Kremer, Joel
Wallenstein, Gene
Kanik, Keith S.
Connell, Carol
Gruben, David
Zwillich, Samuel H.
Fleischmann, Roy